Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, Europe Commercial | May 05, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 55,755 |
Reported balance
After 2026-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-05 · Sale · Disposed 30,000 · Balance 55,755 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2026 Filed May 7, 2026 20:01 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 30,000 | $35.40 | $1,062,000.00 |
DisclosureSEC source: 0001193125-26-211833 · ownership.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,755 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 17,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-098512 · ownership.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,887 Underlying: Ordinary Shares · 17,295 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 17,295 vested on March 5, 2026, 17,295 vesting on each of March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 17,295 vested on March 5, 2026, 17,295 vesting on each of March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 17,295 | $31.67 | $547,704.98 |
DisclosureSEC source: 0001193125-26-098512 · ownership.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,755 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F4 · shares: Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 17,295 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-098512 · ownership.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 33,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096584 · ownership.xml · derivative · entry 8 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,424 Underlying: Ordinary Shares · 33,424 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F9 · derivative.exercise_date: Restricted share units were granted on March 4, 2026, with 8,356 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030. F9 · derivative.expiration_date: Restricted share units were granted on March 4, 2026, with 8,356 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,461 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096584 · ownership.xml · derivative · entry 7 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,923 Underlying: Ordinary Shares · 20,461 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 20,461 vested on each of March 4, 2025 and March 4, 2026, 20,461 vesting on March 4, 2027, and 20,462 vesting on March 4, 2028. F8 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 20,461 vested on each of March 4, 2025 and March 4, 2026, 20,461 vesting on March 4, 2027, and 20,462 vesting on March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 33,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-096584 · ownership.xml · derivative · entry 6 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 33,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 37,372 | $32.95 | $1,231,310.23 |
DisclosureSEC source: 0001193125-26-096584 · ownership.xml · nonDerivative · entry 5 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,755 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.905 to $33.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 20,461 | $32.46 | $664,256.13 |
DisclosureSEC source: 0001193125-26-096584 · ownership.xml · nonDerivative · entry 4 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,127 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F4 · shares: Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-096584 · ownership.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 33,512 | $32.46 | $1,087,950.32 |
DisclosureSEC source: 0001193125-26-096584 · ownership.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,127 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F4 · shares: Represents with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:17 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 33,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-096584 · ownership.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 141,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-093945 · ownership.xml · derivative · entry 6 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 141,478 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria. F7 · derivative.expiration_date: Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 62,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-093945 · ownership.xml · derivative · entry 5 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,253 Underlying: Ordinary Shares · 62,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 62,250 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 4, 2027. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 62,250 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 4, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 66,735 | $32.36 | $2,159,537.93 |
DisclosureSEC source: 0001193125-26-093945 · ownership.xml · nonDerivative · entry 4 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,127 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F4 · shares: Represents (1) with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting, and (2) with respect to the restricted share units granted subject to performance criteria, the reporting person sold such number of shares required to cover tax witholding obligations in connection with the vesting. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 141,478 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-093945 · ownership.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 62,250 | $32.36 | $2,014,403.78 |
DisclosureSEC source: 0001193125-26-093945 · ownership.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,384 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. F4 · shares: Represents (1) with respect to the vesting of restricted share units, the reporting person sold all such shares vested, including shares to cover tax witholding obligations in connection with the vesting, and (2) with respect to the restricted share units granted subject to performance criteria, the reporting person sold such number of shares required to cover tax witholding obligations in connection with the vesting. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 62,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-093945 · ownership.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · EVP, Europe Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 141,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-029306 · ownership.xml · derivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,478 Underlying: Ordinary Shares · 141,478 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionStock Options (right to buy) · Derivative | 15,011 | $0.00 Strike: $16.99 | $0.00 |
DisclosureSEC source: 0001193125-25-315938 · ownership.xml · derivative · entry 5 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,011 shares Expires 2027-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Stock options were granted on September 18, 2017, with 7,505 vested on September 18, 2018, and 7,506 vested on September 18, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionStock Options (right to buy) · Derivative | 100,457 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001193125-25-315938 · ownership.xml · derivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 100,457 shares Expires 2028-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 33,485 vested on each of February 9, 2020 and February 9, 2021, and 33,487 vested on February 9, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 115,468 | $28.68 | $3,311,125.73 |
DisclosureSEC source: 0001193125-25-315938 · ownership.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,384 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.635 to $28.765, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,011 | $16.99 | $255,036.89 |
DisclosureSEC source: 0001193125-25-315938 · ownership.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 100,457 | $18.61 | $1,869,504.77 |
DisclosureSEC source: 0001193125-25-315938 · ownership.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 30,015 | $15.91 | $477,634.70 |
DisclosureSEC source: 0000950170-25-034607 · ownership.xml · nonDerivative · entry 9 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,769 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 7,108 | $15.91 | $113,111.03 |
DisclosureSEC source: 0000950170-25-034607 · ownership.xml · nonDerivative · entry 6 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 11,641 | $15.91 | $185,245.56 |
DisclosureSEC source: 0000950170-25-034607 · ownership.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 69,182 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-035489 · ownership.xml · derivative · entry 5 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,182 Underlying: Ordinary Shares · 69,182 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 5, 2025, with 17,295 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029. F7 · derivative.expiration_date: Restricted share units were granted on March 5, 2025, with 17,295 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 17,297 vesting on March 5, 2029. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 22,576 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-035489 · ownership.xml · derivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 22,576 vested on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 22,576 vested on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 48,385 | $15.90 | $769,369.89 |
DisclosureSEC source: 0000950170-25-035489 · ownership.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,384 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.9 to $15.905, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 22,576 | $15.91 | $359,272.21 |
DisclosureSEC source: 0000950170-25-035489 · ownership.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,769 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.795 to $16.01, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 22,576 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-035489 · ownership.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 12,936 | $15.56 | $201,253.11 |
DisclosureSEC source: 0000950170-25-033566 · ownership.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.455 to $15.75, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 183,169 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034607 · ownership.xml · derivative · entry 12 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 183,169 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F9 · derivative.exercise_date: Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025. F9 · derivative.expiration_date: Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 20,461 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034607 · ownership.xml · derivative · entry 11 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,384 Underlying: Ordinary Shares · 20,461 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F8 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 20,461 vested on March 4, 2025, 20,461 vesting on each of March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028. F8 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 20,461 vested on March 4, 2025, 20,461 vesting on each of March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 33,512 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-034607 · ownership.xml · derivative · entry 10 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,512 Underlying: Ordinary Shares · 33,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026. F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 56,385 | $15.73 | $887,195.42 |
DisclosureSEC source: 0000950170-25-034607 · ownership.xml · nonDerivative · entry 8 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,784 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024. F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 183,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034607 · ownership.xml · nonDerivative · entry 7 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 183,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 13,353 | $15.73 | $210,104.11 |
DisclosureSEC source: 0000950170-25-034607 · ownership.xml · nonDerivative · entry 5 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,108 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 20,461 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034607 · ownership.xml · nonDerivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 21,870 | $15.73 | $344,115.70 |
DisclosureSEC source: 0000950170-25-034607 · ownership.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,641 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 33,512 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-034607 · ownership.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 62,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-033566 · ownership.xml · derivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,503 Underlying: Ordinary Shares · 62,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 62,250 vested on each of March 3, 2024 and March 3, 2025, 62,250 vesting on March 3, 2026, and 62,253 vesting on March 3, 2027. F6 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 62,250 vested on each of March 3, 2024 and March 3, 2025, 62,250 vesting on March 3, 2026, and 62,253 vesting on March 3, 2027. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 49,314 | $16.19 | $798,171.75 |
DisclosureSEC source: 0000950170-25-033566 · ownership.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,936 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.86 to $16.53, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:12 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 62,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-033566 · ownership.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 183,169 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-011080 · ownership.xml · derivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,169 Underlying: Ordinary Shares · 183,169 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2025. F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2025. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 20:09 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 98,943 | $17.30 | $1,711,446.75 |
DisclosureSEC source: 0000950170-24-096198 · ownership.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 55,226 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-027986 · ownership.xml · derivative · entry 6 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 55,226 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F7 · derivative.exercise_date: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024. F7 · derivative.expiration_date: Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 22,576 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-027986 · ownership.xml · derivative · entry 5 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,576 Underlying: Ordinary Shares · 22,576 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 22,576 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025. F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 22,576 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:20 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 26,053 | $13.52 | $352,116.72 |
DisclosureSEC source: 0000950170-24-027986 · ownership.xml · nonDerivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,943 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.